Our firm is investigating cases where patients or family members believe a fatal heart complication is linked to Onglyza or another diabetes medication. New data suggests these medications, used to treat Type 2 diabetes, may increase the risk of heart failure and serious injury.
If you or a loved one has suffered a heart attack or heart failure you may be eligible to seek financial compensation. Our defective drug attorneys provide free consultations and do not get paid unless you are successfully awarded for your injuries.
In April 2015, an FDA advisory panel concluded that patients who take Onglyza (saxagliptin) face an increased risk of heart failure – a fatal condition in which the heart is unable to adequately pump blood to the heart, interrupting all biological functioning. One study concluded that Onglyza increased the risk of heart failure by as much as 27 percent.
Due to this increased risk of death, the agency recommended that the drug’s manufacturer, AstraZeneca, update the drug’s label to warn patients of this potential increased risk of heart failure.
Early signs of heart failure include:
Heart failure is an extremely serious complication which presents serious complication, including physical, emotional and financial devastation to patients and families. Families affected by this possible link to Onglyza should consider filing a heart failure lawsuit.
While our firm is investigating cases of heart failure linked to Onglyza and other medications, research also shows a possible connection between Onglyza and chronic pancreatitis, which may lead to pancreatic cancer.
Symptoms of pancreatitis could include: Severe upper abdominal pain which may radiate through the back, nausea and vomiting, high or low blood pressure, and elevated heart or respiratory rates.
Developed jointly by AstraZeneca and Bristol-Myers Squibb, Onglyza is now owned wholly by AstraZeneca. It was approved by the FDA in July 2009 for the treatment of type 2 diabetes. The medication is part of a class of drugs known as incretin mimetics.
Incretin mimetics are diabetic medications that mimic incretin hormones the body usually produces to naturally stimulate the release of insulin in response to a meal.
Other widely used incretin mimetics under scrutiny include Januvia, Janumet, Byetta and Victoza. Several lawsuits allege that the makers of these medications failed to properly warn users about the increased risk of pancreatic cancer.
Phillips Law Group understands the overwhelming nature of taking a medication that was doing more harm than good. We also understand the complicated and complex process many victims suffer to demand compensation for their pain and suffering.
We are here to help streamline the process. We believe individuals who have suffered injury or the loss of a loved one due to Onglyza and diabetes drug side effects have the right to pursue just compensation for their damages, including medical bills and pain and suffering, in a personal injury lawsuit.
With many years of experience in dangerous drug litigation, our Arizona attorneys understand what it takes to win in the courtroom. We have each case individually, ensuring that our clients receive the personal attention that they deserve.
Complete a Free Case Review form above to get started today.
